ArticleChina CDC weekly2024
Longitudinal Analysis of Antibody Dynamics in Severe Fever with Thrombocytopenia Syndrome Patients - High-Incidence Regions of China, 2010-2023.
Article in China CDC weekly, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- The holistic rehabilitation from acute severe fever with thrombocytopenia syndrome virus infection to 10 years after recovery: A cross-sectional study.Biosafety and health · 2025Article
- Longitudinal analysis of cytokine dynamics in severe fever with thrombocytopenia syndrome patients - High-incidence regions of China (2010-2023).Biosafety and health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
What is already known about this topic?: Severe fever with thrombocytopenia syndrome (SFTS) is a serious tick-borne disease in East Asia with high mortality, particularly affecting the elderly. Since its discovery in 2010, inconsistencies in small-scale studies and the lack of decade-long research on antibody levels in large population samples after natural infection, along with the absence of an effective vaccine, highlight the need for large-scale, long-term data in high-incidence regions of China. What is added by this report?: This study of 1,410 serum samples from SFTS patients in high-incidence regions of China reveals that immunoglobulin M (IgM) levels peak at 8-14 days post-infection, declining to nearly undetectable levels by 180 days. Immunoglobulin G (IgG) and neutralizing antibodies (NAb) levels peak at 22-180 days, persisting up to 10 years. IgM levels correlate with viral load and various immune and coagulation parameters, with lower levels observed in fatal cases. During convalescence, elderly patients have lower IgG levels, whereas females exhibit higher IgG levels compared with males. What are the implications for public health practice?: The study's findings on long-term antibody dynamics in SFTS patients can significantly improve vaccine development, optimize therapy scheduling, inform public health policies, and enhance diagnostic tools, leading to better disease management and prevention in high-incidence areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.